Abstract

Staphylococcus hominis is the third most frequent opportunistic pathogen in neonates and immunosuppressed patients that cause bacteremia, septicemia, endophthalmitis, and endocarditis. The emergence of methicillin resistant Staphylococcus hominis (MRSHo) has been reported and is a growing concern. This review was intended to determine the susceptibility of Staphylococcus hominis to antibiotic agents with pharmacokinetics/pharmacodynamic approach. In addition, this review was determined the phenotypic criteria and antibiotic choice of Staphylococcus hominis infection. Four databases i.e., PubMed, PlosOne, ScienceDirect and Google Scholar were employed in searching process. Antibiotic resistance was identified using the minimum inhibitory concentration (MIC) and the percentage of resistance. The breakpoint value was based on The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MIC and zone diameters Version 11.0. There were 876 articles identified, 35 duplications were removed. These gave a total of 841 articles were screened yet 820 articles were irrelevant. Eventually, 21 articles were reviewed in this report. This review found that Staphylococcus hominis is potentially had MDR activity and a possible XDR bacterium that resistant to some antibacterial agents. The susceptibility of antibiotic to bacteria is not identical, and the regional reported drug resistance varies commonly due to differences in environment and antibiotic use. The resistance profile of Staphylococcus hominis is a complex interaction that affected by multifactorial such as: pharmacokinetics/pharmacodynamics index, mutant prevention concentration (MPC), mutant selection window (MSW), and the capability to produce biofilm.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call